Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
Ryan Allway August 17th, 2022 Psychedelics, Top News TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced... Read more
Lev Secures $41.5 Million in Cannabis CRE Financing Across the U.S., Breaking Down Barriers to Federal Loans in the Market
August 17, 2022
Ryan Allway August 17th, 2022 News, Top News In a highly regulated industry full of red tape, Lev is leading the commercial cannabis boom, helping clients to close quickly with funding from federal institutions NEW YORK, Aug. 17, 2022 /PRNewswire/ — Lev, the commercial real estate (CRE) financing platform, today announced the... Read more
Adastra Expands Market Footprint Through Receipt of Medical Sales License from Health Canada
August 17, 2022
Ryan Allway August 17th, 2022 News, Top News LANGLEY, BC / ACCESSWIRE / August 17, 2022 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) (“Adastra” or the “Company”), a leading cannabis company focused on processing, product development, sales, organoleptic testing and analytical testing, is pleased to announce it has received its Medical Sales... Read more
Cannabis Pioneer Joe Caltabiano Donates $250,000 to Gateway for Cancer ResearchSM to Improve Pediatric Cancer Treatment Options
August 16, 2022
CHICAGO (August 16, 2022) — With a goal to help researchers find a new treatment approach for children fighting cancer recurrence, cannabis industry pioneer Joe Caltabiano has made a transformative gift of $250,000 to Gateway for Cancer ResearchSM (Gateway), a nonprofit organization dedicated to funding transformational early-phase cancer research.... Read more
Cannabis Global Provides Patent Applications Update – Company Files Response to US Patent Office Relative to Cannabis Nanoparticle Application
August 16, 2022
Ryan Allway August 16th, 2022 News, Top News LOS ANGELES, CA / ACCESSWIRE / August 16, 2022 / Cannabis Global, Inc. (OTC PINK:CBGL), Cannabis Global, Inc., a licensed Los Angeles-based manufacturer and distributor in the cannabis sector, today provides an update concerning the Company’s patent applications, especially relating to its... Read more
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and distribute additional psychedelic substances, most... Read more
Verano Introduces New Flower and Extract Brand, Savvy, in Seven Core Cannabis Markets
August 15, 2022
Ryan Allway August 15th, 2022 News, Top News Savvy will launch in September 2022 in Arizona, Florida, Illinois, Massachusetts, Maryland, Nevada and Ohio, with additional launches planned in the future for New Jersey and Pennsylvania Across the Company’s national retail footprint, Savvy products will initially be distributed to approximately 85... Read more
Ryan Allway August 15th, 2022 Psychedelics, Top News Vermont ketamine treatment facility added to fast-growing chain of psychedelic mental-health clinics LOS ANGELES, Aug. 15, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of its first Vermont clinic, continuing what has... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections
August 10, 2022
Ryan Allway August 10th, 2022 News, Top News ARDS-003 is a novel therapeutic for acute systemic inflammation and prevention of acute respiratory distress syndrome (ARDS). ARDS-003 may offer steroid-sparing opportunities. ARDS-003 has demonstrated antiviral properties. ARDS-003 developed as an oral formulation for an immediate release administration. OTTAWA, ON, Aug. 10,... Read more
